Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.062 +0.002 (+0.23%)
Streaming Delayed Price Updated: 10:31 AM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Top 5 Health Care Stocks That May Surge ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
How Is The Market Feeling About Fate Therapeutics? ↗
Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 20.24 million shares sold short, which is 27.85% of all... 
Via Benzinga
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
What 6 Analyst Ratings Have To Say About Fate Therapeutics ↗
 
Via Benzinga
News headline image
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC ↗
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
News headline image
Dow Jumps 700 Points; S&P 500 Rises Over 2% ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. 
Via Benzinga
News headline image
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's trading, 71 companies set new 52-week lows. 
Via Benzinga
News headline image
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Why Is Fate Therapeutics (FATE) Stock Down 62% Today? ↗
Fate Therapeutics (FATE) stock is falling on Friday after the company announced the termination of its collaboration with Janssen Biotech. 
Via InvestorPlace
News headline image
Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging ↗
The Nasdaq Composite once again is underperforming the rest of the market. 
Via The Motley Fool
News headline image
Fate Therapeutics Ends Collaboration Deal With Janssen, Cuts Staff ↗
 
Via Benzinga
News headline image
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amarin To Rally 138%? Here Are 10 Other Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket ↗
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cathie Wood Can't Keep Hands Off Tesla As Holiday Season Binge Grows To Nearly Half A Million Shares ↗
Cathie Wood-led ARK Investment Management bought 21,050 shares of Tesla Inc (NASDAQ: TSLA) on Wednesday at an estimated valuation of over $2.39 million. 
Via Benzinga
News headline image
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Cathie Wood Loads Up Another $2M In Tesla While Elon Musk Urges Employees To Look Beyond Stock Plunge ↗
As Tesla Inc (NASDAQ: TSLA) shares witnessed a surprise rebound on Wednesday, Cathie Wood-led ARK Investment Management 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗
 
Via Benzinga
News headline image
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models 
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022 ↗
 
Via Benzinga
News headline image
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.